Bristol Myers Squibb PE Ratio 2010-2023 | BMY
Current and historical p/e ratio for Bristol Myers Squibb (BMY) from 2010 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Bristol Myers Squibb PE ratio as of May 29, 2023 is 8.19.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Bristol Myers Squibb PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2023-05-26 |
63.82 |
|
18.61 |
| 2023-03-31 |
68.76 |
$3.43 |
20.05 |
| 2022-12-31 |
70.81 |
$2.95 |
24.00 |
| 2022-09-30 |
69.43 |
$3.07 |
22.62 |
| 2022-06-30 |
75.21 |
$3.01 |
24.99 |
| 2022-03-31 |
70.83 |
$2.82 |
25.12 |
| 2021-12-31 |
59.51 |
$3.12 |
19.07 |
| 2021-09-30 |
56.47 |
$-2.40 |
0.00 |
| 2021-06-30 |
62.79 |
$-2.27 |
0.00 |
| 2021-03-31 |
59.32 |
$-2.78 |
0.00 |
| 2020-12-31 |
57.84 |
$-4.01 |
0.00 |
| 2020-09-30 |
55.36 |
$-0.11 |
0.00 |
| 2020-06-30 |
53.58 |
$-0.10 |
0.00 |
| 2020-03-31 |
50.38 |
$0.81 |
62.20 |
| 2019-12-31 |
57.61 |
$2.19 |
26.31 |
| 2019-09-30 |
45.14 |
$3.47 |
13.01 |
| 2019-06-30 |
40.02 |
$3.80 |
10.53 |
| 2019-03-31 |
41.73 |
$3.16 |
13.21 |
| 2018-12-31 |
45.06 |
$3.03 |
14.87 |
| 2018-09-30 |
53.47 |
$0.88 |
60.76 |
| 2018-06-30 |
47.33 |
$0.23 |
205.76 |
| 2018-03-31 |
53.74 |
$0.56 |
95.97 |
| 2017-12-31 |
51.74 |
$0.59 |
87.69 |
| 2017-09-30 |
53.49 |
$2.54 |
21.06 |
| 2017-06-30 |
46.43 |
$2.75 |
16.89 |
| 2017-03-31 |
44.99 |
$2.88 |
15.62 |
| 2016-12-31 |
48.03 |
$2.65 |
18.12 |
| 2016-09-30 |
44.01 |
$2.04 |
21.57 |
| 2016-06-30 |
60.03 |
$1.74 |
34.50 |
| 2016-03-31 |
51.87 |
$0.97 |
53.47 |
| 2015-12-31 |
55.52 |
$0.97 |
57.24 |
| 2015-09-30 |
47.52 |
$1.06 |
44.83 |
| 2015-06-30 |
52.79 |
$1.07 |
49.34 |
| 2015-03-31 |
50.88 |
$1.35 |
37.69 |
| 2014-12-31 |
46.56 |
$1.20 |
38.80 |
| 2014-09-30 |
39.84 |
$1.63 |
24.44 |
| 2014-06-30 |
37.48 |
$1.62 |
23.14 |
| 2014-03-31 |
39.86 |
$1.74 |
22.91 |
| 2013-12-31 |
40.78 |
$1.55 |
26.31 |
| 2013-09-30 |
35.01 |
$1.67 |
20.96 |
| 2013-06-30 |
33.54 |
$0.82 |
40.90 |
| 2013-03-31 |
30.65 |
$0.88 |
34.83 |
| 2012-12-31 |
24.00 |
$1.15 |
20.87 |
| 2012-09-30 |
24.60 |
$1.09 |
22.57 |
| 2012-06-30 |
25.95 |
$2.08 |
12.48 |
| 2012-03-31 |
24.12 |
$2.22 |
10.87 |
| 2011-12-31 |
24.94 |
$2.15 |
11.60 |
| 2011-09-30 |
21.98 |
$1.93 |
11.39 |
| 2011-06-30 |
20.29 |
$1.92 |
10.57 |
| 2011-03-31 |
18.30 |
$1.93 |
9.48 |
| 2010-12-31 |
17.89 |
$1.79 |
9.99 |
| 2010-09-30 |
18.31 |
$5.57 |
3.29 |
| 2010-06-30 |
16.65 |
$5.50 |
3.03 |
| 2010-03-31 |
17.60 |
$5.46 |
3.22 |
| 2009-12-31 |
16.45 |
$5.35 |
3.07 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$134.076B |
$46.159B |
|
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
|
